- Current report filing (8-K)
September 08 2010 - 11:41AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 8, 2010
MAP PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
Delaware
|
|
001-33719
|
|
20-0507047
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
2400 Bayshore Parkway, Suite 200, Mountain
View, CA
|
|
94043
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (650) 386-3100
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (
see
General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
In a press release issued
on September 8, 2010, MAP Pharmaceuticals, Inc. (the Company) provided an update on the clinical development program for its LEVADEX product candidate for the potential treatment of acute migraine, including the completion of
patient treatment in certain of its clinical trials. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits
|
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press Release of MAP Pharmaceuticals, Inc., dated September 8, 2010
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: September 8, 2010
|
|
|
MAP PHARMACEUTICALS, INC.
|
|
|
By:
|
|
/
S
/ C
HARLENE
A.
F
RIEDMAN
|
Name:
|
|
Charlene A. Friedman
|
Title:
|
|
Vice President, General Counsel and Secretary
|
INDEX TO EXHIBITS FILED WITH
THE CURRENT REPORT ON FORM 8-K DATED SEPTEMBER 8, 2010
|
|
|
Exhibit
|
|
Description
|
|
|
99.1
|
|
Press Release of MAP Pharmaceuticals, Inc., dated September 8, 2010
|
Map Pharmaceuticals, Inc. (MM) (NASDAQ:MAPP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Map Pharmaceuticals, Inc. (MM) (NASDAQ:MAPP)
Historical Stock Chart
From Jul 2023 to Jul 2024